Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial | Zendy

Ole S. Søgaard | Zendy; Nicolai Lohse | Zendy; Zitta Barrella Harboe | Zendy; Rasmus Offersen | Zendy; Anne Bukh | Zendy; Heather L. Davis | Zendy; Henrik Carl Schønheyder | Zendy; Lars Østergaard | Zendy

Open Access

Improving the Immunogenicity of Pneumococcal Conjugate Vaccine in HIV‐Infected Adults with a Toll‐Like Receptor 9 Agonist Adjuvant: A Randomized, Controlled Trial

Author(s) -

Ole S. Søgaard,

Nicolai Lohse,

Zitta Barrella Harboe,

Rasmus Offersen,

Anne Bukh,

Heather L. Davis,

Henrik Carl Schønheyder,

Lars Østergaard

Publication year - 2010

Publication title -

clinical infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.44

H-Index - 336

eISSN - 1537-6591

pISSN - 1058-4838

DOI - 10.1086/653112

Subject(s) - medicine , immunogenicity , adjuvant , pneumococcal conjugate vaccine , immunology , placebo , vaccination , clinical endpoint , tlr9 , gastroenterology , antibody , randomized controlled trial , streptococcus pneumoniae , antibiotics , microbiology and biotechnology , biochemistry , gene expression , chemistry , alternative medicine , dna methylation , pathology , gene , biology

Persons infected with human immunodeficiency virus (HIV) are often hyporesponsive to immunization, including pneumococcal vaccines. We hypothesized that adding CPG 7909, a toll-like receptor 9 (TLR9) agonist and vaccine adjuvant, to 7-valent pneumococcal conjugate vaccine (7vPnC) would increase its immunogenicity in HIV-infected adults.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research